TTD Suspends 4 Employees For Following Non-Hindu Faiths
Last Updated: Breaking News India
The Tirumala Tirupati Devasthanams (TTD) has suspended four of its employees over allegations that they were following religious faiths other than Hinduism.The suspended employees include B Elizar, Deputy Executive Engineer (Quality Control); S Rosi, Staff Nurse at BIRRD Hospital; M Premavati, Grade-1 Pharmacist at BIRRD Hospital; and Dr G Asuntha from the SV Ayurveda Pharmacy. n18oc_breaking-newsn18oc_indiaNews18 Mobile App - https://onelink.to/desc-youtube
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
5 hours ago
- Mint
NRIs turning to India for high-quality quality affordable healthcare, customers up 150% YoY in FY25: Report
New Delhi [India], July 28 (ANI): Non-Resident Indians (NRIs) are increasingly choosing India as their destination for high-quality and affordable healthcare, according to the data released by Policybazaar. The data showed a significant 150 per cent growth in the share of NRI customers in FY 2024-25 compared to FY 2023-24, highlighting India's growing appeal in the global medical tourism space. It stated, "India is fast emerging as one of the world's most sought-after medical tourism hubs. The growth is quite visible with more NRIs turning to India to access high-quality healthcare. Our data indicates a 150 per cent overall growth in the share of NRI customers in FY 25". One of the key reasons behind this mentioned in the data report is the surge is the massive cost advantage India offers for medical treatments when compared to countries like the United States and the United Kingdom. For instance, heart bypass surgery in India costs between USD 5,000 and USD 8,000, while the same procedure in the U.S. can cost between USD 70,000 and USD 150,000. Similarly, a knee replacement surgery costs only USD 4,000 to USD 6,000 in India, compared to USD 30,000 to USD 50,000 in the U.S. A liver transplant in India is priced between USD 25,000 and USD 35,000, whereas it costs USD 300,000 to USD 500,000 in the U.S. NRIs opting for elective procedures in India typically have average claim amounts ranging from USD 2,000 to USD 15,000. For more complex surgeries, the claims may rise to USD 20,000 to USD 40,000, still representing considerable savings when compared to international healthcare costs. The affordability factor also extends to health insurance premiums. In India, the average annual health insurance premium per person ranges from USD 120 to USD 300. In contrast, the same coverage in the U.S. can exceed USD 8,000 annually, while in GCC countries, it ranges from USD 4,000 to USD 5,000. This significant difference has led to a visible increase in online searches by NRIs exploring health insurance options in India for themselves and their families. The data further reveals a 125 per cent surge in the share of women NRI customers and a 148 per cent increase in the number of NRI customers under the age of 35. This showed that younger NRIs and women are increasingly considering Indian healthcare as a preferred choice. When it comes to preferred locations for treatment, South Indian cities continue to dominate the list across all tiers. Cities like Mumbai, Kolkata, Pune, and Thane are also gaining popularity among NRI patients. With a combination of quality care, advanced medical infrastructure, and substantial cost benefits, India is rapidly emerging as a leading hub for NRI medical needs. (ANI)
Economic Times
16 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Don't know the actual reason behind Dhankhar's resignation: Kharge
Congress President Mallikarjun Kharge on Sunday said he has no information on the actual reason for Jagdeep Dhankhar resigning as Vice-President. After Jagdeep Dhankhar resigned on the evening of July 21 citing ill health, Congress and other opposition parties suggested that there is more to it than meets the eye, hinting at a rift between Dhankhar and the government. "Dhankhar has to tell what really happened, as the matter is between him and Prime Minister Narendra Modi," he added. In his resignation letter to President Droupadi Murmu, Dhankhar said he was stepping down with immediate effect to "prioritise health care." Speaking to reporters here, Kharge said, "When we raised several issues concerning farmers, the poor, international issues, or foreign policy, he never used to give us an opportunity (in Rajya Sabha, as its Chairman)." "When we tried to raise issues by giving notices—on issues regarding the poor, atrocities against women, Dalits and the downtrodden, and incidents like Hindu-Muslim clashes—he did not give us an opportunity. It (the reason for Dhankhar's resignation as Vice-President) is between him and Modi. We don't have any information on that," he added.
